Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19
Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19
Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and
 Adverse Outcomes in Hospitalized Patients With Coronavirus Infection.
Several interactions by pre-existing therapies for chronic diseases, therapies used by
 SARS-CoV2 infection generate doubts about risks and benefits. Among these situations in which
 the current data indicate a situation of equipoise would be about the maintenance or
 suspension of ACEI / BRA in patients with SARS-CoV2 infection. Increasing the expression of
 ECA-2 could increase the binding to the virus, however, there are studies that indicate this
 increase in ECA-2 could be protective. So far, there is no clinical evidence to confirm any
 of the theories, and this question can only be clarified through a randomized clinical trial.

 The objective is to evaluate the impact of the suspension of the use of
 angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (BRA) on the
 length of hospital stay and on the mortality of patients with SARS-CoV2 infection.
Inclusion Criteria:

 -  Patients hospitalized with COVID-19 diagnosis using ACE inhibitors or blockers of
 angiotensin receptor;

 -  Patients ≥ 18 years old;

 -  Maximum use of 3 antihypertensive drugs;

 -  Sign the consent form.

 Exclusion Criteria:

 -  Severe evolution with orotracheal intubation, use of mechanical ventilation and / or
 hemodynamic instability in the first 24 hours until COVID-19 diagnosis confirmation;

 -  Patients hospitalized per decompensated congestive heart failure in the last 12
 months;

 -  Use of Sacubitril/Valsartan

 -  Pregnancy

 -  Recent acute renal failure and shock